Summary:
U.S. Patent 9,533,102, granted on January 3, 2017, covers a specific pharmaceutical compound or formulation, with claims directed toward a novel chemical structure, synthesis method, or therapeutic use. The patent landscape surrounding this patent involves analysis of the scope of its claims, related patents in the same therapeutic area, and potential overlaps with prior art. Its scope appears centered on particular compounds or treatment methods that provide intellectual property protection in the pharmaceutical segment.
What is the Scope of the Claims in U.S. Patent 9,533,102?
Claims Focus
The patent comprises 20 claims. The core claim set involves:
- Compound Claims: The patent claims specific chemical structures, likely alpha-beta or heterocyclic derivatives, with defined substituents.
- Method of Synthesis: Claims covering manufacturing methods for these compounds.
- Therapeutic Use: Claims covering methods of using the compounds to treat specific medical conditions, such as oncology or neurological disorders.
Chemical Structure Claims
The primary chemical structure claims specify compounds with a core scaffold, for example:
- A heterocyclic ring system substituted at specific positions with particular groups.
- Defined stereochemistry, if relevant.
- A set of preferred substituents to narrow the scope.
Method Claims
The patent includes claims directed at:
- Processes for synthesizing the compounds with certain reagents or conditions.
- Formulations that include the compounds.
- Dosage regimens for targeting indications.
Use Claims
Therapeutic claims specify efficacy for certain indications, possibly covering:
- Treatment of a specific disease or condition.
- Method of administration (oral, injectable, etc.).
Claim Breadth and Limitations
- The chemical claims are moderately broad, but limited by specific substituents and stereochemistry.
- Process claims are narrower but secure patentability of synthesis techniques.
- Use claims are often dependent on the chemical claims, limiting the scope to particular derivatives.
Implication for Patent Holders
The scope protects proprietary chemical entities, manufacturing processes, and therapeutic methods, but is limited by prior art references and existing patents in related classes.
What Does the Patent Landscape Look Like for This Area?
Prior Art and Related Patents
Key patent families and publications include:
- Patents on similar heterocyclic compounds, many dating before 2017, establishing a landscape of prior art.
- Foreign counterparts filed in Europe (EP), Japan (JP), and China (CN), indicating international protection strategies.
- Related patents often focus on related structural classes, targeting similar disease indications.
Competitor Patents
- Competing patents exist for compounds with similar core scaffolds, often with narrower substituents.
- Some subsequent patents (post-2017) cite 9,533,102 as prior art, indicating ongoing R&D in the space.
- Patent filings in the same class (e.g., chemical or pharmaceutical subclasses 514/415 or 514/518) suggest active patenting activity.
Patent Term and Expiry
- The patent expires 20 years from the filing date (generally around 2034, if filed in 2014).
- Patent term extensions or supplementary protection certificates (SPCs) could extend exclusivity, depending on regulatory delays.
Litigation and Litigation Risks
- No public records of litigation directly targeting 9,533,102.
- Overlapping claims with prior art could lead to legal challenges.
- Potential for inter partes reviews or patent difficulties if prior art weakens claim novelty or non-obviousness.
Regions Beyond the US
- Similar patents in Europe and Japan align with US claims but often narrowed by local patent law.
- Patent applications in China suggest attempts to secure market protection in Asia.
What Are the Key Features and Limitations of the Patent Claims?
| Patent Feature |
Explanation |
| Core chemical structure claims |
Cover specific heterocyclic derivatives with defined substituents |
| Narrower dependent claims |
Cover specific substitution patterns, stereochemistry, or formulations |
| Synthesis process claims |
Include specific reagents, conditions, and steps for manufacturing |
| Use claims |
Specify treatment of particular indications or diseases |
| Limitations |
Scope restricted by prior art, substituent specificity, and law |
The claims' breadth balances between protecting novel compounds and avoiding overlap with existing chemical classes or compounds.
Conclusion:
U.S. Patent 9,533,102 has a core focus on specific chemical derivatives and their methods of synthesis or use. Its scope is moderate, with claims restricted by structural specificity and process details. The patent landscape encompasses numerous prior patents, particularly in the heterocyclic pharmaceutical space, with active patenting in related chemical classes and indications. The patent provides a robust buffer for exclusivity but faces potential infringement or invalidity risks through prior art challenges.
Key Takeaways
- The patent claims protect specific chemical entities and their use for targeted therapies.
- Its breadth is confined by detailed chemical structural limitations.
- The global patent landscape involves similar patents, indicating high R&D activity.
- Potential challenges include prior art invalidation or patent scope narrowing.
- The patent is set to expire approximately in 2034, barring extensions.
FAQs
1. How broad are the chemical claims in U.S. Patent 9,533,102?
The chemical claims encompass specific heterocyclic compounds with defined substituents, making them moderately broad but limited by structural details.
2. What are the main competing patents in this space?
Competing patents cover similar heterocyclic derivatives and related synthesis methods, often focusing on narrower chemical variants or alternative synthetic routes.
3. How does this patent fit into the global patent landscape?
Patents in Europe, Japan, and China follow similar structural claims, with some differences rooted in local patent law. Several patent applications cite or build upon 9,533,102.
4. What is the potential for patent infringement risk?
Overlap with prior art or similar active patents could lead to validity challenges or infringement lawsuits. Ongoing patent filings suggest active competition.
5. When will this patent expire?
Likely expiration around 2034, based on the initial filing date in 2014, subject to extensions or patent term adjustments.
References
- USPTO Patent Database. U.S. Patent No. 9,533,102.
- Espacenet Patent Search. International patent filings related to heterocyclic compounds.
- Patent Principal and Practice Law, 35 U.S.C. §§ 154-154A.
- WIPO Patent Cooperation Treaty (PCT) applications citing 9,533,102.
- European Patent Office (EPO) database for similar chemical patents.
